Jump to content

Selected press releases

  • Press release - 18/08/2022

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on mRNA, today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant.

  • Press release - 18/08/2022

    University of Tübingen team discovers how malformations of the blood vessels can occur in mice – yielding information with possible ramifications for retinal disease.

  • Press release - 04/08/2022

    In mice, inflammation in early to mid-life leads to a permanent decline in functional blood stem cells, according to a recent publication by scientists from the German Cancer Research Center (DKFZ) and the Stem Cell Institute HI-STEM*. The ability of the blood stem cells to regenerate was suppressed for at least one year after challenge with inflammation.

  • Press release - 29/07/2022

    A centre for model-based artificial intelligence has been set up at Heidelberg University to link mathematical modelling methods with information processing in neuronal networks. The Carl Zeiss Foundation (CZS) is funding the CZS Heidelberg Center for Model-Based AI with five million euros over a period of six years.

  • Press release - 29/06/2022

    Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.

  • Press release - 23/06/2022

    Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A team of Heidelberg physicians and scientists has now shown in a clinical study: Increased serum levels of the characteristic cytokines occur frequently in cancer patients, but clinically relevant cases of the dreaded syndrome were not…

  • Press release - 21/06/2022

    Scientists from the 2. Physics Institute at the University of Stuttgart and the Max Planck Institute for Medical Research were now able to take the next step towards synthetic cells: They introduced functional DNA-based cytoskeletons into cell-sized compartments and showed functionality. The results were recently published in Nature Chemistry.

  • Press release - 20/06/2022

    Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.

  • Press release - 03/06/2022

    The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.

  • Press release - 12/05/2022

    Microrobots have the potential to revolutionize medicine. Researchers at the Max Planck ETH Centre for Learning Systems have now developed an imaging technique that for the first time recognises cell-sized microrobots individually and at high resolution in a living organism. This is an important step towards precise control of the robots and their clinical translation.

  • Press release - 12/05/2022

    While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release